Valproic Acid in Treating Patients With Kaposi's Sarcoma

NACompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

February 29, 2008

Conditions
Sarcoma
Interventions
DRUG

valproic acid

250 mg by mouth twice a day

Trial Locations (13)

10021

Memorial Sloan-Kettering Cancer Center, New York

10461

Albert Einstein Cancer Center at Albert Einstein College of Medicine, The Bronx

19106

Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia

30303

Georgia Cancer Center for Excellence at Grady Memorial Hospital, Atlanta

63110

Siteman Cancer Center at Barnes-Jewish Hospital, St Louis

92161

Veterans Affairs Medical Center - San Diego, San Diego

98111

Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center, Seattle

90095-1781

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

94143-0324

UCSF Comprehensive Cancer Center, San Francisco

60611-3013

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

02215

Beth Israel Deaconess Medical Center, Boston

44106-5065

Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

The Emmes Company, LLC

INDUSTRY

lead

AIDS Malignancy Consortium

NETWORK

NCT00075777 - Valproic Acid in Treating Patients With Kaposi's Sarcoma | Biotech Hunter | Biotech Hunter